Babyscripts Announces Commercial Partnership with Roche Diagnostics

Share Article

Roche and Babyscripts to collaborate on the next generation of integrated women’s health solutions

News Image
Roche’s investment in Babyscripts solutions is a tremendous validation of our vision for improving maternal care, and an example of the kind of strategic collaboration essential to moving the needle on outcomes.

Babyscripts, the leading virtual care platform for managing obstetrics, today announced a commercial partnership with Roche Diagnostics, a division of the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics. Roche Diagnostics and Babyscripts will collaborate on the next generation of digital and diagnostic combinations in women’s health.

Under the terms of this collaboration, Roche will partner with Babyscripts on the development of Babyscripts’ remote patient monitoring (RPM) programs to leverage groundbreaking data science through the next generation of RPM in pregnancy. These programs will be focused on solving issues of blood pressure-related complications through RPM, such as prenatal hypertension. Babyscripts participated in Startup Creasphere, Roche's digital health accelerator program, which was instrumental in initiating this collaboration.

“Roche’s investment in Babyscripts solutions is a tremendous validation of our vision for improving maternal care, and an example of the kind of strategic collaboration essential to moving the needle on outcomes,” said Juan Pablo Segura, co-founder and President of Babyscripts. “Roche’s vast expertise in the field of women’s health diagnostics and clinical science combined with our on-the-ground experience in the virtual maternal health space is going to prove a game changer for rethinking how we approach prenatal and postpartum care.”

Roche has a long history of innovation in the women’s maternal health space, yielding a portfolio of fertility and prenatal tests that deliver highly accurate results, such as ElecsysⓇ AMH testing to help understand a women’s fertility status to improve chances of conception and HarmonyⓇ non-invasive prenatal testing that assesses the probability for trisomies 21, 18, 13. These advanced diagnostic and screening tests empower couples and clinicians to make decisions from pregnancy planning to birth. Through the collaboration with Babyscripts, Roche will continue their commitment to bringing innovative, data-driven and integrated solutions to pregnant and postpartum mothers.

Babyscripts has spent the last six years building a clinically-validated, virtual care platform to allow OBGYNs to deliver a new model of prenatal and postpartum care. Using internet-connected devices for remote monitoring, Babyscripts offers risk-specific experiences to allow providers to manage up to 90% of pregnancies virtually, allowing doctors to detect risk more quickly and automate elements of care.

About Babyscripts
Babyscripts is delivering a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their healthcare providers. We’ve spent the last six years delivering the most-implemented mobile clinical solution for remote monitoring in pregnancy, with the mission to eliminate maternal mortality and improve access to care for all mothers. Babyscripts was named to the 2020 Digital Health 150, CB Insights’ annual ranking of the 150 most promising private digital health companies in the world. For more information on our virtual care solution and to request a demo, visit

Disclaimer: The Harmony Prenatal Test was developed by Ariosa Diagnostics, a CLIA-certified laboratory. As with other lab-developed tests, it has not been cleared or approved by the FDA and is not available for sale as an IVD in the US. Non-invasive prenatal testing (NIPT) based on cell-free DNA analysis is not diagnostic; results should be confirmed by diagnostic testing."

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Stacy Callahan
Visit website